Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 5/2017

01-05-2017 | Review Article

Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors

Authors: Emmanuelle Vigarios, Joel B. Epstein, Vincent Sibaud

Published in: Supportive Care in Cancer | Issue 5/2017

Login to get access

Abstract

Development of biological targeted therapies and immune checkpoint inhibitors has redefined the treatment for many cancers; however, the increasing use of new protocols has led to physicians observing a new spectrum of toxicities. To date, oral adverse events induced by these new anticancer therapies have been mainly reported using nonspecific terminology (“stomatitis,” “mucosal inflammation,” “mucositis”) and remain poorly characterized, with the exception of mammalian target of rapamycin (mTOR) inhibitor-associated stomatitis. Oral toxicities of targeted therapies often display very characteristic features which clearly differ from classic oral injuries observed with cytotoxic chemotherapy and/or radiotherapy. In addition, they frequently affect more than 20% of treated patients and can lead to a significant morbidity or permanent treatment discontinuation. Oral mucosal toxicities described in this review include mTOR inhibitor-associated stomatitis (mIAS); stomatitis, benign migratory glossitis, and osteonecrosis of the jaw associated with multi-targeted kinase inhibitors of the VEGF and PDGF receptors; mucositis induced by EGFR inhibitors (in monotherapy or in combination with head and neck radiotherapy and/or chemotherapy); hyperkeratotic lesions with BRAF inhibitors; pigmentary changes and lichenoid reactions secondary to imatinib; and more recent data on the “Osler-Weber-Rendu-like syndrome” described with the antibody-drug conjugate, TDM-1. Finally, we provide, to our knowledge, the first available structured data on oral toxicities induced by the new recently FDA- and EMA-approved monoclonal antibodies targeting PD-1. Clinical management of these targeted therapy-related oral changes is also discussed.
Literature
1.
Sacco AG, Cohen EE (2015) Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma. J Clin Oncol 33:3305–3313PubMedCrossRef
2.
3.
4.
Johnson DB, Pollack MH, Sosman JA (2016) Emerging targeted therapies for melanoma. Expert Opin Emerg Drugs 21:195–207PubMedCrossRef
5.
Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372:2006–2017PubMedCrossRef
6.
Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ et al (2015) Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16:257–265PubMedCrossRef
7.
Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T et al (2015) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16:1473–1482PubMedCrossRef
8.
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532PubMedCrossRef
9.
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330PubMedCrossRef
10.
11.
12.
Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A (2015) Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane. J Am Acad Dermatol 72:203–218PubMedCrossRef
13.
Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A (2015) Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol 72:221–236PubMedCrossRef
14.
Robert C, Sibaud V, Mateus C, Cherpelis BS (2012) Advances in the management of cutaneous toxicities of targeted therapies. Semin Oncol 39:227–240PubMedCrossRef
15.
Robert C, Mateus C, Spatz A, Wechsler J, Escudier B (2009) Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 60:299–305PubMedCrossRef
16.
Fakih M, Vincent M (2010) Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr Oncol 17(Suppl 1):S18–S30PubMedPubMedCentral
17.
Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P et al (2005) Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 6:491–500PubMedCrossRef
18.
Reyes-Habito CM, Roh EK (2014) Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: part II. Targeted therapy. J Am Acad Dermatol 71:217.e1–217.e11CrossRefPubMed
19.
Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME et al (2015) Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 26:2375–2391PubMed
20.
Sibaud V, Meyer N, Lamant L, Vigarios E, Mazieres J, Delord JP (2016) Dermatologic complications of anti-PD-1/PD-L-1 immune checkpoint antibodies. Curr Opinion Oncol 28:254–263CrossRef
21.
Sibaud V, Boralevi F, Vigarios E, Fricain JC (2014) Oral toxicity of targeted anticancer therapies. Ann Dermatol Venereol 141:354–363 [Article in French]PubMedCrossRef
22.
Martins F, de Oliveira MA, Wang Q, Sonis S, Gallottini M, George S et al (2013) A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients. Oral Oncol 49:293–298PubMedCrossRef
23.
Watters AL, Epstein JB, Agulnik M (2011) Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol 47:441–448PubMedCrossRef
24.
Jensen SB, Peterson DE (2014) Oral mucosal injury caused by cancer therapies: current management and new frontiers in research. J Oral Pathol Med 43:81–90PubMedCrossRef
25.
Yuan A, Kurtz SL, Barysauskas CM, Pilotte AP, Wagner AJ, Treister NS (2015) Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors. Oral Oncol 51:1026–1033PubMedCrossRef
26.
Al-Ansari S, Zecha JA, Barasch A, de Lange J, Rozema FR, Raber-Durlacher JE (2015) Oral mucositis induced by anticancer therapies. Curr Oral Health Rep 2:202–211PubMedPubMedCentralCrossRef
27.
Sonis S, Treister N, Chawla S, Demetri G, Haluska F (2010) Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 116:210–215PubMed
28.
Boers-Doets CB, Epstein JB, Raber-Durlacher JE, Ouwerkerk J, Logan RM, Brakenhoff JA et al (2012) Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 17:135–144PubMedCrossRef
29.
Gomez-Fernandez C, Garden BC, Wu S, Feldman DR, Lacouture ME (2012) The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. Eur J Cancer 48:340–346PubMedCrossRef
30.
Elting LS, Chang YC, Parelkar P, Boers-Doets CB, Michelet M, Hita G et al (2013) Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. Support Care Cancer 21:3243–3254PubMedCrossRef
31.
Vigarios E, Lamant L, Delord JP, Fricain JC, Chevreau C, Barrés B et al (2015) Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors. Br J Dermatol 172:1680–1682PubMedCrossRef
32.
De Oliveira MA, Martins E, Martins F, Wang Q, Sonis S, Demetri G et al (2011) Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol 47:998–1003PubMedCrossRef
33.
Peterson DE, Boers-Doets CB, Bensadoun RJ, Herrstedt J, Guidelines Committee ESMO (2015) Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol 26:v139–v151PubMedCrossRef
34.
Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020–1030PubMedPubMedCentralCrossRef
35.
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE et al (2015) Nivolumab versus docetaxel in advanced non squamous non-small-cell lung cancer. N Engl J Med 373:1627–1639PubMedCrossRef
36.
McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O et al (2016) Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol 34:833–842PubMedCrossRef
37.
Jackson LK, Johnson DB, Sosman JA, Murphy BA, Epstein JB (2015) Oral health in oncology: impact of immunotherapy. Support Care Cancer 23:1–3PubMedCrossRef
38.
Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M et al (2016) Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol 152:1128–1136PubMedCrossRef
39.
Shameem R, Lacouture M, Wu S (2015) Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients. Cancer Investig 33:70–77CrossRef
40.
Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stockfleth E (2010) mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transpl 24:149–156CrossRef
41.
Vargo CA, Berger MJ, Phillips G, Mrozek E (2016) Occurrence and characterization of everolimus adverse events during first and subsequent cycles in the treatment of metastatic breast cancer. Support Care Cancer 24:2913–2918PubMed
42.
Rugo HS, Hortobagyi GN, Yao J, Pavel M, Ravaud A, Franz D et al (2016) Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Ann Oncol 27:519–525PubMedPubMedCentralCrossRef
43.
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514–523PubMedPubMedCentralCrossRef
44.
Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520–529PubMedCrossRef
45.
Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ et al (2016) Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol 17:378–388PubMedCrossRef
46.
André F, O’Regan R, Ozguroglu M, Toi M, Xu B, Jerusalem G et al (2014) Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15:580–591PubMedCrossRef
47.
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803–1813PubMedCrossRef
48.
Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F et al (2015) Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1814–1823PubMedPubMedCentralCrossRef
49.
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281PubMedCrossRef
50.
Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L et al (2013) Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 31:195–202PubMedCrossRef
51.
Hutson TE, Escudier B, Esteban E, Bjarnason GA, Lim HY, Pittman KB et al (2014) Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 32:760–767PubMedCrossRef
52.
Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer AG, Hariharan S et al (2014) Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 32:752–759PubMedCrossRef
53.
Ansell SM, Tang H, Kurtin PJ, Koenig PA, Inwards DJ, Shah K et al (2011) Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 12:361–368PubMedPubMedCentralCrossRef
54.
Park K, Tan EH, O’Byrne K, Zhang L, Boyer M, Mok T et al (2016) Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol 17:577–589PubMedCrossRef
55.
Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW et al (2012) Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 13:528–538PubMedCrossRef
56.
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15:213–222PubMedCrossRef
57.
Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB et al (2015) Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol 16:583–594PubMedCrossRef
58.
Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH et al (2015) Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol 16:897–907PubMedCrossRef
59.
Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327–3334PubMedCrossRef
60.
Harbeck N, Huang CS, Hurvitz S, Yeh DC, Shao Z, Im SA et al (2016) Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol 17:357–366PubMedCrossRef
61.
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743PubMedCrossRef
62.
Goss PE, Smith IE, O’Shaughnessy J, Ejlertsen B, Kaufmann M, Boyle F et al (2013) Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol 14:88–96PubMedCrossRef
63.
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957PubMedCrossRef
64.
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121–128PubMedCrossRef
65.
Ramalingam SS, Jänne PA, Mok T, O’Byrne K, Boyer MJ, Von Pawel J et al (2014) Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol 15:1369–1378PubMedCrossRef
66.
Ciuleanu T, Stelmakh L, Cicenas S, Miliauskas S, Grigorescu AC, Hillenbach C et al (2012) Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol 13:300–308PubMedCrossRef
67.
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735–742PubMedCrossRef
68.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132PubMedCrossRef
69.
Ellis PM, Shepherd FA, Millward M, Perrone F, Seymour L, Liu G et al (2014) Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. Lancet Oncol 15:1379–1388PubMedCrossRef
70.
Jänne PA, Ou SH, Kim DW, Oxnard GR, Martins R, Kris MG et al (2014) Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. Lancet Oncol 15:1433–1441PubMedCrossRef
71.
Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345PubMedCrossRef
72.
Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P et al (2014) Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 15:569–579PubMedCrossRef
73.
Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28PubMedCrossRef
74.
Magrini SM, Buglione M, Corvò R, Pirtoli L, Paiar F, Ponticelli P et al (2016) Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial. J Clin Oncol 34:427–435PubMedCrossRef
75.
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567–578PubMedCrossRef
76.
Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS et al (2014) Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol 32:2940–2950PubMedPubMedCentralCrossRef
77.
Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G et al (2013) Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 14:490–499PubMedCrossRef
78.
Kim ES, Neubauer M, Cohn A, Schwartzberg L, Garbo L, Caton J et al (2013) Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol 14:1326–1336PubMedCrossRef
79.
Primrose J, Falk S, Finch-Jones M, Valle J, O’Reilly D, Siriwardena A et al (2014) Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 15:601–611PubMedCrossRef
80.
Vermorken JB, Stöhlmacher-Williams J, Davidenko I, Licitra L, Winquist E, Villanueva C et al (2013) Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 14:697–710PubMedCrossRef
81.
Leone F, Marino D, Cereda S, Filippi R, Belli C, Spadi R et al (2016) Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: a randomized phase 2 trial (Vecti-BIL study). Cancer 122:574–581PubMedCrossRef
82.
Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C et al (2013) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 14:481–489PubMedPubMedCentralCrossRef
83.
Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J et al (2014) Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 15:286–296PubMedCrossRef
84.
Motzer RJ, Escudier B, Tomczak P, Hutson TE, Michaelson MD, Negrier S et al (2013) Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14:552–562PubMedCrossRef
85.
Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S et al (2013) Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 31:4067–4075PubMedCrossRef
86.
Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369:722–731PubMedCrossRef
87.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124PubMedCrossRef
88.
Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513PubMedCrossRef
89.
Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S et al (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10:757–763PubMedCrossRef
90.
Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH et al (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31:3639–3646PubMedPubMedCentralCrossRef
91.
Tournigand C, Chibaudel B, Samson B, Scheithauer W, Vernerey D, Mésange P et al (2015) Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Lancet Oncol 16:1493–1505PubMedCrossRef
92.
O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1004PubMedCrossRef
93.
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480PubMedCrossRef
94.
Raymond E, Brandes AA, Dittrich C, Fumoleau P, Coudert B, Clement PM et al (2008) Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol 26:4659–4665PubMedPubMedCentralCrossRef
95.
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385–2394PubMedCrossRef
96.
Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R et al (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963–1971PubMedPubMedCentralCrossRef
97.
Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB et al (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13:1011–1019PubMedPubMedCentralCrossRef
98.
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167–2177PubMedCrossRef
99.
Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD et al (2012) Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366:2171–2179PubMedPubMedCentralCrossRef
100.
Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L et al (2015) Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol 16:729–736PubMedCrossRef
101.
Rugo HS (2016) Dosing and safety implications for oncologists when administering everolimus to patients with hormone receptor-positive breast cancer. Clin Breast Cancer 16:18–22PubMedCrossRef
102.
Rugo HS, Pritchard KI, Gnant M, Noguchi S, Piccart M, Hortobagyi G et al (2014) Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol 25:808–815PubMedPubMedCentralCrossRef
103.
Sonis ST (2009) Mucositis: the impact, biology and therapeutic opportunities of oral mucositis. Oral Oncol 45:1015–1020PubMedCrossRef
104.
105.
Nishimura N, Nakano K, Ueda K, Kodaira M, Yamada S, Mishima Y et al (2012) Prospective evaluation of incidence and severity of oral mucositis induced by conventional chemotherapy in solid tumors and malignant lymphomas. Support Care Cancer 20:2053–2059PubMedCrossRef
106.
Elad S, Raber-Durlacher JE, Brennan MT, Saunders DP, Mank AP, Zadik Y et al (2015) Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT). Support Care Cancer 23:223–236PubMedCrossRef
107.
Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM et al (2014) MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 120:1453–1461PubMedPubMedCentralCrossRef
108.
Peterson ME (2013) Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial. Support Care Cancer 21:2341–2349PubMedPubMedCentralCrossRef
109.
McGuire DB, Fulton JS, Park J, Brown CG, Correa ME, Eilers J et al (2013) Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer 21:3165–3177PubMedCrossRef
110.
Peterson DE, O’Shaughnessy JA, Rugo HS, Elad S, Schubert MM, Viet CT et al (2016) Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Cancer Med 5:1897–1907PubMedPubMedCentralCrossRef
111.
Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ et al. (2016) Prevention of everolimus/exemestane stomatitis in postmenopausal women with hormone receptor–positive metastatic breast cancer using a dexamethasone-based mouthwash: results of the SWISH Trial. ASCO Ann Meeting, Poster, June 3–7 2016 Chicago, Illinois
112.
Porta C, Osanto S, Ravaud A, Climent MA, Vaishampayan U, White DA et al (2011) Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 47:1287–1298PubMedCrossRef
113.
Zecha JA, Raber-Durlacher JE, Nair RG, Epstein JB, Elad S, Hamblin MR et al (2016) Low-level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols. Support Care Cancer 24:2793–2805PubMedCrossRef
114.
Paplomata E, Zelnak A, O’Regan R (2013) Everolimus: side effect profile and management of toxicities in breast cancer. Breast Cancer Res Treat 140:453–462PubMedCrossRef
115.
Porta C, Paglino C, Imariso I, Canipari C, Chen K, Neary M et al (2011) Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. BMC Cancer 11:105–113PubMedPubMedCentralCrossRef
116.
Kwitkowski VE, Prowell TM, Ibrahim A, Farrell AT, Justice R (2010) Mitchell SS et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma Oncologist 15:428–435PubMed
117.
Tuccori M, Lapi F, Testi A, Ruggiero E, Moretti U, Vannacci A et al (2011) Drug-induced taste and smell alterations: a case/non-case evaluation of an italian database of spontaneous adverse drug reaction reporting. Drug Saf 34:849–859PubMedCrossRef
118.
Mosel DD, Bauer RL, Lynch DP, Hwang ST (2011) Oral complications in the treatment of cancer patients. Oral Dis 17:550–559PubMedCrossRef
119.
Zabernigg A, Gamper EM, Giesinger JM, Rumpold G, Kemmler G, Gattringer K et al (2010) Taste alterations in cancer patients receiving chemotherapy: a neglected side effect? Oncologist 15:913–920PubMedPubMedCentralCrossRef
120.
Imai H, Soeda H, Komine K, Otsuka K, Shibata H (2013) Preliminary estimation of the prevalence of chemotherapy-induced dysgeusia in Japanese patients with cancer. BMC Palliat Care 12:38PubMedPubMedCentralCrossRef
121.
Epstein JB, Barasch A (2010) Taste disorders in cancer patients: pathogenesis, and approach to assessment and management. Oral Oncol 46:77–81PubMedCrossRef
122.
Nagraj SK, Naresh S, Srinivas K, Renjith George P, Shrestha A, Levenson D et al (2014) Interventions for the management of taste disturbances. Cochrane Database Syst Rev 11:CD010470
123.
Kim DW, Jung YS, Park HS, Jung HD (2013) Osteonecrosis of the jaw related to everolimus: a case report. Br J Oral Maxillofac Surg 51:e302–e304PubMedCrossRef
124.
Hamadeh IS, Ngwa BA, Gong Y (2015) Drug induced osteonecrosis of the jaw. Cancer Treat Rev 41:455–464PubMedCrossRef
125.
Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB et al (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19:1079–1095PubMedPubMedCentralCrossRef
126.
Lacouture ME, Lai SE (2006) The PRIDE (papulopustules and/or paronychia, regulatory abnormalities of hair growth, itching, and dryness due to epidermal growth factor receptor inhibitors) syndrome. Br J Dermatol 155:852–854PubMedCrossRef
127.
Chen P, Wang L, Liu B, Zhang HZ, Liu HC, Zou Z (2011) EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis. Eur J Clin Pharmacol 67:235–243PubMedCrossRef
128.
Burotto M, Manasanch EE, Wilkerson J, Fojo T (2015) Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials. Oncologist 20:400–410PubMedPubMedCentralCrossRef
129.
Melosky B, Hirsh V (2014) Management of common toxicities in metastatic NSCLC related to anti-lung cancer therapies with EGFR-TKIs. Front Oncol 4:238PubMedPubMedCentral
130.
Miroddi M, Sterrantino C, Simonelli I, Ciminata G, Phillips RS, Calapai G (2015) Risk of grade 3–4 diarrhea and mucositis in colorectal cancer patients receiving anti-EGFR monoclonal antibodies regimens: a meta-analysis of 18 randomized controlled clinical trials. Crit Rev Oncol Hematol 96:355–371PubMedCrossRef
131.
Lv ZC, Ning JY, Chen HB (2014) Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials. Tumour Biol 35:11741–11750PubMedCrossRef
132.
Bonner JA, Giralt J, Harari PM, Baselga J, Spencer S, Bell D et al (2016) Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: assessment from a phase 3 registration trial. Eur J Cancer 64:1–11PubMedCrossRef
133.
Tejwani A, Wu S, Jia Y, Agulnik M, Millender L, Lacouture ME (2009) Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. Cancer 115:1286–1299PubMedCrossRef
134.
Lacouture ME, Maitland ML, Segaert S, Setser A, Baran R, Fox LP et al (2010) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18:509–522PubMedCrossRef
135.
Pryor DI, Burmeister E, Burmeister BH, Poulsen MG, Porceddu SV (2011) Distinct patterns of stomatitis with concurrent cetuximab and radiotherapy for head and neck squamous cell carcinoma. Oral Oncol 47:984–987PubMedCrossRef
136.
Zhu G, Lin JC, Kim SB, Bernier J, Agarwal JP, Vermorken JB et al (2016) Asian expert recommendation on management of skin and mucosal effects of radiation, with or without the addition of cetuximab or chemotherapy, in treatment of head and neck squamous cell carcinoma. BMC Cancer 16:42PubMedPubMedCentralCrossRef
137.
Kollmannsberger C, Bjarnason G, Burnett P, Creel P, Davis M, Dawson N et al (2011) Sunitinib in metastatic renal cell carcinoma: recommendations for management of non-cardiovascular toxicities. Oncologist 16:543–553PubMedPubMedCentralCrossRef
138.
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484–2496PubMedCrossRef
139.
Ibrahim EM, Kazkaz GA, Abouelkhair KM, Bayer AM, Elmasri OA (2013) Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis. Int J Clin Oncol 18:1060–1069PubMedCrossRef
140.
Edmonds K, Hull D, Spencer-Shaw A, Koldenhof J, Chrysou M, Boers-Doets C et al (2012) Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group. Eur J Oncol Nurs 16:172–184PubMedCrossRef
141.
Gavrilovic IT, Balagula Y, Rosen AC, Ramaswamy V, Dickler MN, Dunkel IJ et al (2012) Characteristics of oral mucosal events related to bevacizumab treatment. Oncologist 17:274–278PubMedPubMedCentralCrossRef
142.
Hubiche T, Valenza B, Chevreau C, Fricain JC, Del Giudice P, Sibaud V (2013) Geographic tongue induced by angiogenesis inhibitors. Oncologist 18:e16–e17PubMedPubMedCentralCrossRef
143.
Rosen AC, Gavrilovic IT, Balagula Y, Ramaswamy V, Dickler MN et al (2013) Geographic tongue induced by angiogenesis inhibitors: in reply. Oncologist 18:e18PubMedPubMedCentralCrossRef
144.
145.
Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G et al (2009) Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76:209–211PubMedCrossRef
146.
Ponzetti A, Pinta F, Spadi R, Mecca C, Fanchini L, Zanini M et al. (2016) Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district. Tumori 102(Suppl. 2)
147.
Fusco V, Santini D, Armento G, Tonini G, Campisi G (2016) Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology. Expert Opin Drug Saf 15:925–935PubMedCrossRef
148.
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B et al (2014) American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 72:1938–1956PubMedCrossRef
149.
Gaudin E, Seidel L, Bacevic M, Rompen E, Lambert F (2015) Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis. J Clin Periodontol 42:922–932PubMedCrossRef
150.
Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3–23PubMedCrossRef
151.
Goodday RH (2015) Preventive strategies for patients at risk of medication-related osteonecrosis of the jaw. Oral Maxillofac Surg Clin North Am 27:527–536PubMedCrossRef
152.
Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME (2008) Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 16:557–566PubMedCrossRef
153.
Gómez Fernández C, Sendagorta Cudós E, Casado Verrier B, Feito Rodríguez M, Suárez Aguado J, Vidaurrázaga Díaz de Arcaya C (2010) Oral lichenoid eruption associated with imatinib treatment. Eur J Dermatol 20:127–128PubMed
154.
Amitay-Laish I, Stemmer SM, Lacouture ME (2011) Adverse cutaneous reactions secondary to tyrosine kinase inhibitors including imatinib mesylate, nilotinib, and dasatinib. Dermatol Ther 24:386–395PubMedCrossRef
155.
Zhang JA, Yu JB, Li XH, Zhao L (2015) Oral and cutaneous lichenoid eruption with nail changes due to imatinib treatment in a chinese patient with chronic myeloid leukemia. Ann Dermatol 27:228–229PubMedPubMedCentralCrossRef
156.
Wahiduzzaman M, Pubalan M (2008) Oral and cutaneous lichenoid reaction with nail changes secondary to imatinib: report of a case and literature review. Dermatol Online J 14:14PubMed
157.
Pascual JC, Matarredona J, Miralles J, Conesa V, Borras-Blasco J (2006) Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases. Int J Dermatol 45:1471–1473PubMedCrossRef
158.
Ena P, Chiarolini F, Siddi GM, Cossu A (2004) Oral lichenoid eruption secondary to imatinib (Glivec). J Dermatolog Treat 15:253–255PubMedCrossRef
159.
Basso FG, Boer CC, Correa MEP, Torrezan M, Cintra ML, Gallotini de Magalhaes MHC et al (2009) Skin and oral lesions associated to imatinib mesylate therapy. Support Care Cancer 17:465–468PubMedCrossRef
160.
Fitzpatrick SG, Hirsch SA, Gordon SC (2014) The malignant transformation of oral lichen planus and oral lichenoid lesions: a systematic review. J Am Dent Assoc 145:45–56PubMedCrossRef
161.
Wong M, Sade S, Gilbert M, Klieb HB (2011) Oral melanosis after tyrosine kinase inhibition with imatinib for chronic myelogenous leukemia: report of a case and review of the literature. Dermatol Online J 17:4PubMed
162.
Khoo TL, Catalano A, Supple S, Chong L, Yeoh SC, Yeung S et al (2013) Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT. Leuk Lymphoma 54:186–188PubMedCrossRef
163.
Yu YH, Shere Y, Vigneswaran N (2012) Oral and maxillofacial pathology case of the month. Palatal melanosis associated with imatinib mesylate therapy. Tex Dent J 129(764–5):786–788
164.
Mattsson U, Halbritter S, Mörner Serikoff E, Christerson L, Warfvinge G (2011) Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 111:e12–e16PubMedCrossRef
165.
Li CC, Malik SM, Blaeser BF, Dehni WJ, Kabani SP, Boyle N et al (2012) Mucosal pigmentation caused by imatinib: report of three cases. Head Neck Pathol 6:290–295PubMedCrossRef
166.
Yuan A, Woo SB (2015) Adverse drug events in the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol 119:35–47PubMedCrossRef
167.
Balagula Y, Pulitzer MP, Maki RG, Myskowski PL (2011) Pigmentary changes in a patient treated with imatinib. J Drugs Dermatol 10:1062–1066PubMed
168.
Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F et al (2016) Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 13:473–486PubMedCrossRef
169.
Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS (2016) Nivolumab in resected and Unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22:886–894PubMedCrossRef
170.
Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550PubMedCrossRef
171.
Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S et al (2016) Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60:190–209PubMedCrossRef
172.
Schaberg KB, Novoa RA, Wakelee HA, Kim J, Cheung C, Srinivas S et al (2016) Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol 43:339–346PubMedCrossRef
173.
Lacouture ME, Duvic M, Hauschild A, Prieto VG, Robert C, Schadendorf D et al (2013) Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 18:314–322PubMedPubMedCentralCrossRef
174.
Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N et al (2013) Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 24:1691–1697PubMedCrossRef
175.
Gençler B, Gönül M (2016) Cutaneous side effects of BRAF inhibitors in advanced melanoma: review of the literature. Dermatol Res Pract 2016:5361569PubMedPubMedCentral
176.
Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R et al (2012) RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 30:316–321PubMedCrossRef
177.
Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS et al (2012) Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study. J Am Acad Dermatol 67:1265–1272PubMedPubMedCentralCrossRef
178.
Mangold AR, Bryce A, Sekulic A (2014) Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma. J Am Acad Dermatol 71:e205–e206PubMedCrossRef
179.
Pileri A, Cricca M, Gandolfi L, Misciali C, Casadei B, Zinzani PL et al (2015) Vemurafenib mucosal side-effect. J Eur Acad Dermatol Venereol 30:1053–1055PubMedCrossRef
180.
181.
Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM et al (2014) Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol 70:60–69PubMedCrossRef
182.
Epstein JB, Smutzer G, Doty RL (2016) Understanding the impact of taste changes in oncology care. Support Care Cancer 24:1917–1931PubMedCrossRef
183.
Sibaud V, Niec RE, Schindler K, Busam KJ, Roché H, Modi S et al (2014) Ado-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series. Breast Cancer Res Treat 146:451–456PubMedCrossRef
184.
Sibaud V, Vigarios E, Combemale P, Lamant L, Lacouture ME, Lacaze JL et al (2015) T-DM1-related telangiectasias: a potential role in secondary bleeding events. Ann Oncol 26:436–437PubMedCrossRef
Metadata
Title
Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors
Authors
Emmanuelle Vigarios
Joel B. Epstein
Vincent Sibaud
Publication date
01-05-2017
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 5/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-017-3629-4

Other articles of this Issue 5/2017

Supportive Care in Cancer 5/2017 Go to the issue

Original Article

Experiences with the survivorship care plan in primary care providers of childhood cancer survivors: a mixed methods approach

Original Article

Role of benzydamine hydrochloride in the prevention of oral mucositis in head and neck cancer patients treated with radiotherapy (>50 Gy) with or without chemotherapy

Original Paper

Hyperacute peripheral neuropathy is a predictor of oxaliplatin-induced persistent peripheral neuropathy

Original Article

Association of worry about cancer to benefit finding and functioning in long-term cancer survivors

Original Article

Fear of recurrence or progression as a link between somatic symptoms and perceived stress among cancer survivors

Original Article

Quality of life of older African American breast cancer survivors: a population-based study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits